Table 13.
Risk‐benefit balance |
The effects of bisphosphonates on bone deformity have not been adequately studied. |
Quality of evidence |
Very low |
Patient values and preferences |
Bone deformity is of concern to patients. If treatment strategies could be identified that were effective in preventing bone deformity, it is likely that they would be favored by patients. |
Costs and use of resources |
Bisphosphonates are inexpensive, but intravenous therapy involves additional support costs and costs in terms of patient time attending for the infusion that may need to be considered. |
Recommendation |
There is insufficient evidence that bisphosphonates can prevent or treat bone deformity in PDB, and they are not recommended for this indication. |